scholarly journals Assessment of Low Bone Mineral Density in Untreated Patients with Takayasu’s Arteritis

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Lingfei Mo ◽  
Jing Wang ◽  
BoMiao Ju ◽  
Yanhua Wang ◽  
Jing Luo ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Loss ◽  
Bone Metabolism ◽  
Bone Mineral ◽  
Takayasu’S Arteritis ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Mineral Density ◽  
Low Bone Mineral Density

Chronic inflammation affects bone metabolism and accelerates bone loss. This study is aimed at analyzing the prevalence of low bone mineral density (LBMD) in patients with untreated Takayasu’s arteritis (TA) and risk factors. Forty untreated TA patients were enrolled, including 38 premenopausal women and 2 men before 50 years old. The control group included 60 age- and gender-matched healthy persons. Bone mineral density (BMD) of lumbar vertebrae and hip in patients with TA and the control group was measured by the dual-energy X-ray method. Serum 25OHD and β-CTX were also measured. The lumbar BMD of TA patients ( 0.89 ± 0.11  g/cm2) was significantly lower than that of the healthy control ( 0.97 ± 0.11  g/cm2). The prevalence of LBMD at the lumbar spine (17.50%) was significantly higher than that of the control group (3.33%). However, there was no significant difference at the hip. The 25OHD of TA patients was lower than that of healthy controls, while the level of β-CTX was higher. The levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in patients with LBMD were higher than those in patients with normal BMD. According to univariate correlation analysis, there was a significant negative correlation between LDL-C and lumbar BMD. Binary logistic regression analysis showed that LDL-C was an important factor affecting the occurrence of LBMD in patients with TA ( OR = 25.269 , P = 0.02 ). Our result reveals bone loss in TA patients, which hints the relationship among inflammation, lipid metabolism, and bone metabolism.

Management of bone metabolism in epilepsy

2021 ◽  
Vol 74 (7-8) ◽  
pp. 257-265
Author(s):  
Firdevs Ezgi Uçan Tokuç ◽  
Fatma Genç ◽  
Abidin Erdal ◽  
Yasemin Biçer Gömceli
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Bone Metabolism ◽  
Bone Mineral ◽  
Outpatient Clinic ◽  
Bone Mineralization ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
Increased Risk ◽  
Significant Difference

Many systemic problems arise due to the side effects of antiepileptic drugs (AEDs) used in epilepsy patients. Among these adverse effects are low bone mineral density and increased fracture risk due to long-term AED use. Although various studies have supported this association with increased risk in recent years, the length of this process has not been precisely defined and there is no clear consensus on bone density scanning, intervals of screening, and the subject of calcium and vitamin D supplementation. In this study, in accordance with the most current recommendations, our applications and data, including the detection of possible bone mineralization disorders, treatment methods, and recommendations to prevent bone mineralization disorders, were evaluated in epilepsy patients who were followed up at our outpatient clinic. It was aimed to draw attention to the significance of management of bone metabolism carried out with appropriate protocols. Epilepsy patients were followed up at the Antalya Training and Research Hospital Department of Neurology, Epilepsy Outpatient Clinic who were at high risk for osteoporosis (use of valproic acid [VPA] and enzyme-inducing drugs, using any AED for over 5 years, and postmenopausal women) and were evaluated using a screening protocol. According to this protocol, a total of 190 patients suspected of osteoporosis risk were retrospectively evaluated. Four patients were excluded from the study due to secondary osteoporosis. Of the 186 patients who were included in the study, 97 (52.2%) were women and 89 (47.8%) were men. Prevalence of low bone mineral density (BMD) was 42%, in which osteoporosis was detected in 11.8% and osteopenia in 30.6% of the patients. Osteoporosis rate was higher at the young age group (18-45) and this difference was statistically significant (p=0.018). There was no significant difference between male and female sexes according to osteoporosis and osteopenia rates. Patients receiving polytherapy had higher osteoporosis rate and lower BMD compared to patients receiving monotherapy. Comparison of separate drug groups according to osteoporosis rate revealed that osteoporosis rate was highest in patient groups using VPA+ carbamazepine (CBZ) (29.4%) and VPA polytherapy (19.4%). Total of osteopenia and osteoporosis, or low BMD, was highest in VPA polytherapy (VPA+ non-enzyme-inducing AED [NEID]) and CBZ polytherapy (CBZ+NEID) groups, with rates of 58.3% and 55.1%, respectively. In addition, there was no significant difference between drug groups according to bone metabolism markers, vitamin D levels, and osteopenia-osteoporosis rates. Assuming bone health will be affected at an early age in epilepsy patients, providing lifestyle and diet recommendations, avoiding polytherapy including VPA and CBZ when possible, and evaluating bone metabolism at regular intervals are actions that should be applied in routine practice.

scholarly journals Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism

2018 ◽  
Vol 4 (4) ◽  
pp. 37 ◽  
Author(s):  
Giuseppina E. Grieco ◽  
Dorica Cataldo ◽  
Elena Ceccarelli ◽  
Laura Nigi ◽  
Giovanna Catalano ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Type 1 Diabetes ◽  
Bone Loss ◽  
Bone Metabolism ◽  
Bone Remodeling ◽  
Bone Mineral ◽  
Bone Fragility ◽  
Bone Homeostasis ◽  
Mineral Density

Type 1 diabetes (T1D) is characterized by bone loss and altered bone remodeling, resulting into reduction of bone mineral density (BMD) and increased risk of fractures. Identification of specific biomarkers and/or causative factors of diabetic bone fragility is of fundamental importance for an early detection of such alterations and to envisage appropriate therapeutic interventions. MicroRNAs (miRNAs) are small non-coding RNAs which negatively regulate genes expression. Of note, miRNAs can be secreted in biological fluids through their association with different cellular components and, in such context, they may represent both candidate biomarkers and/or mediators of bone metabolism alterations. Here, we aimed at identifying miRNAs differentially expressed in serum of T1D patients and potentially involved in bone loss in type 1 diabetes. We selected six miRNAs previously associated with T1D and bone metabolism: miR-21; miR-24; miR-27a; miR-148a; miR-214; and miR-375. Selected miRNAs were analyzed in sera of 15 T1D patients (age: 33.57 ± 8.17; BMI: 21.4 ± 1.65) and 14 non-diabetic subjects (age: 31.7 ± 8.2; BMI: 24.6 ± 4.34). Calcium, osteocalcin, parathormone (PTH), bone ALkaline Phoshatase (bALP), and Vitamin D (VitD) as well as main parameters of bone health were measured in each patient. We observed an increased expression of miR-148a (p = 0.012) and miR-21-5p (p = 0.034) in sera of T1D patients vs non-diabetic subjects. The correlation analysis between miRNAs expression and the main parameters of bone metabolism, showed a correlation between miR-148a and Bone Mineral Density (BMD) total body (TB) values (p = 0.042) and PTH circulating levels (p = 0.033) and the association of miR-21-5p to Bone Mineral Content-Femur (BMC-FEM). Finally, miR-148a and miR-21-5p target genes prediction analysis revealed several factors involved in bone development and remodeling, such as MAFB, WNT1, TGFB2, STAT3, or PDCD4, and the co-modulation of common pathways involved in bone homeostasis thus potentially assigning a role to both miR-148a and miR-21-5p in bone metabolism alterations. In conclusion, these results lead us to hypothesize a potential role for miR-148a and miR-21-5p in bone remodeling, thus representing potential biomarkers of bone fragility in T1D.

Is there a relationship between premature hair greying and hearing impairment?

2015 ◽  
Vol 129 (11) ◽  
pp. 1097-1100 ◽  
Author(s):  
I Ozbay ◽  
C Kahraman ◽  
C Kucur ◽  
N D Namdar ◽  
F Oghan
Keyword(s):  
Bone Mineral Density ◽  
Hearing Loss ◽  
Hearing Impairment ◽  
Bone Mineral ◽  
High Frequency ◽  
Low Frequency ◽  
Control Group ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
High Frequency Audiometry

AbstractObjective:There is evidence for a strong correlation between low bone mineral density and hearing loss. Furthermore, premature hair greying has been associated with low bone mineral density. Hence, this study aimed to investigate, for the first time, the relationship between premature hair greying and hearing impairment.Methods:Fifty patients with premature hair greying (20 women and 30 men), aged under 40 years (mean, 30.1 ± 4.9 years), who had onset of hair greying in their twenties, were recruited, along with 45 age- and sex-matched healthy control subjects (17 women and 28 men; mean age, 28.7 ± 5.1 years). Each participant was tested with low frequency audiometry at 0.125 to 2 kHz, high frequency audiometry at 4 to 8 kHz, and extended high frequency audiometry at 9 to 20 kHz.Results:Hearing thresholds were similar at all frequencies from 0.25 to 4 kHz (p > 0.05); however, significant hearing loss was observed at all frequencies from 8 to 20 kHz in the premature hair greying group compared with the control group (p < 0.05).Conclusion:Patients with premature hair greying had hearing impairment at extended high frequencies. Premature hair greying may be an important risk factor for hearing loss.

scholarly journals Risk factors for low bone mineral density and the 6-year rate of bone loss among premenopausal and perimenopausal women

2004 ◽  
Vol 15 (6) ◽  
Author(s):  
KathleenE. Bainbridge ◽  
MaryFran Sowers ◽  
Xihong Lin ◽  
SiobanD. Harlow
Keyword(s):  
Risk Factors ◽  
Bone Mineral Density ◽  
Bone Loss ◽  
Bone Mineral ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
Perimenopausal Women ◽  
Rate Of Bone Loss

scholarly journals 309 Effects of dietary supplying icariin on the bone metabolism and the laying performance in caged laying hens

2019 ◽  
Vol 97 (Supplement_3) ◽  
pp. 11-11
Author(s):  
Jie Huang ◽  
Lei Zhang ◽  
Zhongxin Zhou
Keyword(s):  
Bone Mineral Density ◽  
Bone Metabolism ◽  
Bone Mineral ◽  
Laying Hens ◽  
Egg Quality ◽  
Control Group ◽  
Tartrate Resistant Acid Phosphatase ◽  
Mineral Density ◽  
Laying Performance ◽  
Serum Biochemical

Abstract Icariin, a flavonol glycoside, is one of major active ingredients of the traditional Chinese medicine Herba epimedii. Icariin has been reported to successfully treat the osteoporosis of the rat. However, effects of icariin on the osteoporosis in caged laying hens are still unkown. This study present the effects of dietary icariin supplementation on the laying performance, the egg quality and the bone metabolism in caged laying hens. A total of 216 Lohmann pink-shell laying hens of 54-week-old from a commercial farm in the Hubei province of China were randomly assigned to 3 treatment groups with 6 replications per group and 12 birds per replication. The control group was fed a corn-soybean meal basal diet, and the experimental groups were fed basal diets supplemented with 500 and 2000 mg/kg icariin for 90 d. Layer performance responses, egg quality parameters, the bone mineral density and serum biochemical indicators were measured at the end of the experiment. Results showed that feed/egg ratio decreased as the supplied icariin level increased. The laying rate and the average egg weight were increased compared to the control group. However, no significant effect was observed on the egg quality. The bone mineral density of the tibia was measured by the dual-energy X-ray absorptiometry, indicating that icariin can increase the bone mineral density. Serum biochemical analysis showed that icariin decreased the level of alkaline phosphatase, tartrate-resistant acid phosphatase, osteocalcin and calcitonin. Our observations provided evidences that dietary supplementation of icariin increased the bone mineral density and improved the laying performance, and icariin can be used for the prevention of the osteoporosis in caged laying hens.

Комплексная оценка минерально-костных нарушений у женщин с оксалатной нефропатией в постменопаузе

2020 ◽  
pp. 5-10
Keyword(s):  
Bone Mineral Density ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Bone Metabolism ◽  
Bone Mineral ◽  
Calcium Metabolism ◽  
Control Group ◽  
Mineral Density ◽  
High Level ◽  
Oxalate Nephropathy

A study was made of phosphorus-calcium metabolism, markers of bone metabolism, bone mineral density in 142 women in the early postmenopausal period, the patients with oxalate nephropathy at stage 2 of chronic kidney disease. It is proved that patients have signs of secondary hyperparathyroidism (hypocalcemia, hypercalciuria, increased parathyroid hormone) and a deficiency of 25 (OH) D3. Violation of bone metabolism is confirmed by a high level of β-Cross Laps and a decrease in bone mineral density. The probability of a 10-year risk of developing osteoporetic fractures in patients using the FRAX calculator is two times higher than in the control group. The conclusion was made that patients with oxalate nephropathy have a high risk of developing osteoporosis already in the early stages of chronic kidney disease.

Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression

Bone ◽  
2008 ◽  
Vol 42 (3) ◽  
pp. 582-590 ◽  
Author(s):  
Milan Petronijević ◽  
Nataša Petronijević ◽  
Maja Ivković ◽  
Dušan Stefanović ◽  
Nevena Radonjić ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Metabolism ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Unipolar Depression ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
High Bone

scholarly journals High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy

2016 ◽  
Vol 32 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Gerome V. Escota ◽  
Kristin Mondy ◽  
Tim Bush ◽  
Lois Conley ◽  
John T. Brooks ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Antiretroviral Therapy ◽  
Bone Loss ◽  
Bone Mineral ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
High Prevalence
Sign in / Sign up

Export Citation Format

Share Document